Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3065 |
|
Actual shortage: | 231 (8%) | |
Anticipated shortage: | 16 (1%) | |
Avoided shortage: | 9 (0%) | |
Resolved: | 2809 (92%) | |
Discontinuation Reports |
356 |
|
To be discontinued: | 22 (6%) | |
Discontinued: | 334 (94%) | |
Reversed: | 0 (0%) | |
Late reports |
142 (4%) |
|
Overdue reports |
30 (11%) |
Shortage reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-NAPROXEN | 375MG | TABLET | Resolved | 2021-02-05 | 2021-03-30 | 133385 |
APO-NAPROXEN | 375MG | TABLET | Resolved | 2021-02-19 | 2021-03-17 | 134439 |
APO-NAPROXEN | 375MG | TABLET | Resolved | 2021-06-04 | 2021-06-22 | 140420 |
APO-NAPROXEN EC | 375MG | TABLET (ENTERIC-COATED) | Resolved | 2021-06-04 | 2021-06-14 | 140423 |
APO-NAPROXEN EC | 375MG | TABLET (ENTERIC-COATED) | Resolved | 2021-09-24 | 2021-10-05 | 146157 |
APO-NAPROXEN EC | 375MG | TABLET (ENTERIC-COATED) | Resolved | 2022-01-14 | 2022-02-07 | 152770 |
APO-NAPROXEN EC | 375MG | TABLET (ENTERIC-COATED) | Resolved | 2022-08-11 | 2022-10-20 | 166445 |
APO-NAPROXEN | 375MG | TABLET | Resolved | 2022-09-01 | 2022-11-20 | 168421 |
APO-NAPROXEN | 375MG | TABLET | Resolved | 2023-09-07 | 2023-10-13 | 203849 |
ZAMINE 28 | 3MG 0.03MG | TABLET | Resolved | 2021-02-12 | 2021-03-10 | 133984 |
APO-HYDROMORPHONE CR | 3MG | CAPSULE (EXTENDED RELEASE) | Resolved | 2019-01-30 | 2020-04-04 | 74019 |
APO-RIVASTIGMINE | 3MG | CAPSULE | Resolved | 2019-06-12 | 2019-10-07 | 86336 |
APO-RIVASTIGMINE | 3MG | CAPSULE | Resolved | 2021-07-05 | 2021-12-03 | 141854 |
APO-GUANFACINE XR | 3MG | TABLET (EXTENDED-RELEASE) | Resolved | 2022-06-12 | 2022-07-28 | 162475 |
APO-RIVASTIGMINE | 3MG | CAPSULE | Resolved | 2023-09-28 | 2024-01-05 | 205501 |
APO-GUANFACINE XR | 3MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-12-22 | 2024-01-12 | 214220 |
APO-RIVASTIGMINE | 3MG | CAPSULE | Resolved | 2024-05-03 | 2024-05-17 | 227085 |
PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 4.0G 0.5G | POWDER FOR SOLUTION | Actual shortage | 2017-03-11 | 2017-10-05 | 580 |
APO-RISPERIDONE | 4.0MG | TABLET | Resolved | 2019-10-09 | 2019-10-29 | 95882 |
APO-RIVASTIGMINE | 4.5MG | CAPSULE | Resolved | 2017-03-11 | 2017-05-18 | 487 |
Discontinuation reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-IRBESARTAN/HCTZ | Discontinued | 2018-02-23 | 2018-07-17 | 40763 | ||
APO-CETIRIZINE | Discontinued | 2018-05-31 | 2018-05-31 | 50998 | ||
APO-AMOXI CLAV 125MG/31.25MG PER 5ML | Discontinued | 2018-09-07 | 2018-09-15 | 60241 | ||
APO-CYCLOSPORINE ORAL SOLUTION | Discontinued | 2018-09-07 | 2018-09-15 | 60408 | ||
APO-FAMOTIDINE TAB 20MG USP | Discontinued | 2018-09-07 | 2018-09-15 | 60477 | ||
APO-FAMOTIDINE TAB 40MG USP | Discontinued | 2018-09-07 | 2018-09-15 | 60480 | ||
APO-FENTANYL MATRIX | Discontinued | 2018-09-07 | 2018-09-15 | 60494 | ||
APO-IRBESARTAN/HCTZ | Discontinued | 2018-09-07 | 2018-09-15 | 60548 | ||
APO-LATANOPROST-TIMOP | Discontinued | 2018-09-07 | 2018-09-15 | 60572 | ||
APO-REPAGLINIDE | Discontinued | 2018-09-08 | 2018-09-15 | 60735 | ||
APO-REPAGLINIDE | Discontinued | 2018-09-08 | 2018-09-15 | 60738 | ||
APO-REPAGLINIDE | Discontinued | 2018-09-08 | 2018-09-15 | 60741 | ||
APO-RIZATRIPTAN RPD | Discontinued | 2018-09-08 | 2019-04-02 | 60756 | ||
APO-SILDENAFIL R | Discontinued | 2018-09-08 | 2018-09-15 | 60787 | ||
APO-AMOXI CLAV 125MG/31.25MG PER 5ML | Discontinued | 2018-12-21 | 2018-12-24 | 70347 | ||
APO-TIMOP | Discontinued | 2019-01-02 | 2019-01-02 | 70818 | ||
ACID CONTROL | Discontinued | 2019-01-03 | 2019-01-03 | 70906 | ||
APO-OFLOXACIN | Discontinued | 2019-01-03 | 2019-01-03 | 71017 | ||
APO-TIMOP GEL | Discontinued | 2019-01-03 | 2019-01-03 | 71020 | ||
APO-VALSARTAN | Discontinued | 2019-01-03 | 2019-01-03 | 71029 |